logo-loader

TRACON says envafolimab NDA submitted for approval by its partners to the NMPA in China

Published: 13:31 16 Nov 2020 EST

TRACON Pharmaceuticals - TRACON says envafolimab NDA submitted for approval by its partners to the NMPA in China
TRACON Pharmaceuticals CEO Charles Theuer said the submission for approval 'highlights the advanced status of envafolimab product development'

TRACON Pharmaceuticals Inc (NASDAQ:TCON) revealed on Monday that its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug application (NDA) for the approval of envafolimab (KN035) in the indication of MSI-H/dMMR cancer to the National Medical Products Administration (NMPA), in China.

“We congratulate our partners on the regulatory submission of data from the registration trial of envafolimab in MSI-H/dMMR advanced solid tumors including colorectal and gastric cancer, which marks an important milestone in the development and potential commercialization of the program,” TRACON Pharmaceuticals CEO Charles Theuer said in a statament.

“The submission for approval highlights the advanced status of envafolimab product development,” he added.

READ: TRACON Pharmaceuticals strengthens its cash position in 3Q to fund operations into 2022

In addition, envafolimab is being studied in two additional registration trials, a randomized Phase 3 trial in biliary tract cancer in China being conducted by 3D Medicines and Alphamab.

TRACON is also conducting the ENVASARC trial in sarcoma, a rare group of cancers arise in the bones, and connective tissue in the US, in multiple sites.

“We expect to dose multiple patients prior to the end of the year,” added Theuer.

Envafolimab, a novel, single-domain antibody against PD-L1, is the first subcutaneous injected PD-(L)1 inhibitor to be studied in registration trials.

The ENVASARC registration trial is a multi-center, open label, randomized, non-comparative, parallel cohort study at 25 top cancer centers in the US. The company said there’s a planned enrollment for 160 patients, with 80 patients enrolled into cohort A of treatment with single agent envafolimab and 80 patients enrolled in cohort B of treatment with envafolimab and Yervoy.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 37 minutes ago